Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis
| Autor: | Amr Abbass, Ahmed Ghalwash, Heba Omar, Mohamed El Kassas, Mohamed Eltabbakh, Ahmad Sweedy, Sameera Ezzat, Hassan Hamdy, Shimaa Afify, Mohamed Salaheldin, Dalia Omran, Rasha Farghaly, Helmy Elshazly, Nermeen Abdeen, Marwa Tahoon, Mohamed Alboraie, Mohammed Emadeldeen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Liver Cirrhosis
Ledipasvir medicine.medical_specialty Pyrrolidines Daclatasvir Genotype Sustained Virologic Response Sofosbuvir Hepatitis C virus Population Hepacivirus medicine.disease_cause Antiviral Agents Severity of Illness Index End Stage Liver Disease Liver disease chemistry.chemical_compound Internal medicine medicine Humans education Retrospective Studies Fluorenes education.field_of_study Hepatology business.industry Imidazoles Gastroenterology Valine Hepatitis C Hepatitis C Chronic medicine.disease Decompensated cirrhosis Treatment Outcome chemistry Benzimidazoles Drug Therapy Combination Carbamates business medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 33:e877-e882 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0000000000002287 |
| Popis: | BACKGROUND Hepatitis C virus (HCV)-related decompensated cirrhosis is a severe life-threatening illness. The safety of direct-acting antivirals (DAAs) has opened a gate of hope for that subgroup of patients who were previously contraindicated for interferon therapy. OBJECTIVE We aimed at the investigation of the safety and efficacy of different DAAs regimens in the treatment of HCV-related decompensated cirrhosis patients, to determine sustained virological response (SVR)12 rates and to analyze the factors associated with response. METHODS A retrospective, single-center study including HCV-related decompensated cirrhosis patients who received DAAs. Demographic, laboratory and clinical data were analyzed. The SVR12 rate was the primary outcome measure. Secondary outcomes included the predictors of response, changes in the baseline model for end-stage liver disease and child-turcotte-pugh (CTP) scores, and fibroindices (APRI and fibrosis-4 index) at 12 weeks after treatment. RESULTS In total, 145 eligible patients (141 with CTP class B and 4 with class C) were enrolled in this study. SVR12 was achieved by 88.06% (118/134) of efficacy population on different DAAs regimens, Treatment was discontinued in 11 patients because of severe side effects without any deaths. Younger age showed a significant positive association with SVR12. CONCLUSIONS DAAs can be used for the treatment of HCV-related decompensated liver disease, with acceptable SVR12 rates and safety profiles. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|